Evidence map›Paper›PMID 40390204›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Relationships between neuropsychiatric symptoms, subtypes of astrocyte activities, and brain pathologies in Alzheimer's disease and Parkinson's disease.

Oceanna Yueran Li, Steven Shin, Sa Zhou, Adam Turnbull, F Vankee Lin, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oceanna Yueran LiCogT Lab, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.ORCID 0009-0005-0298-4052
Steven ShinCogT Lab, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.
Sa ZhouCogT Lab, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.
Adam TurnbullCogT Lab, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.
F Vankee LinCogT Lab, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.ORCID 0000-0003-1945-0362
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Michael D Greicius · 2020 to 2026
$29.0M
U24 NEW Brain Aging Diversity SupplementU24AG072701 · NIA · UNIVERSITY OF ROCHESTER · PI CONWELL, YEATES, LIN, FENG VANKEE · 2021 to 2024
$2.6M
Characterizing biopsychological mismatch during cognitive training in mild cognitive impairment as a means of improving transferK01AG086665 · NIA · STANFORD UNIVERSITY · PI Adam Turnbull · 2024 to 2026
$378k
4D PharmaAbbvieAbbVieAcureXADNIAligning Science Across Parkinson'sAllerganAlzheimer's AssociationAlzheimer's Disease Neuroimaging InitiativeAlzheimer's Therapeutic Research InstituteAmathus TherapeuticsAraclon BiotechAskBioAvid RadiopharmaceuticalsBIALBioArcticBiogenBiohavenBioLegendBlueRock TherapeuticsCalico LabsCapsida BiotherapeuticsCelgeneCereSpir, Inc.Cerevel TherapeuticsCIHRCoave TherapeuticsCogstateDaCapo BrainscienceDenaliDOD ADNI W81XWH-12-2-0012Edmond J. Safra FoundationEisai Inc.Elan Pharmaceuticals, Inc.Eli LillyEli Lilly and CompanyEuroimmunFujirebioGain TherapeuticsGE HealthcareGenentechGenentech, Inc.Golub CapitalGSKHandl TherapeuticsInsitroIXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLC.Jazz PharmaceuticalsJohnson & Johnson Innovative MedicineJohnson & Johnson Pharmaceutical Research & Development LLC.Laboratory for Neuro Imaging at the University of Southern CaliforniaLumosityLundbeckMerckMeso Scale Diagnostics, LLC.Meso Scale DiscoveryMichael J. Fox Foundation for Parkinson's ResearchMission TherapeuticsNeurocrine BiosciencesNeuron23NeuroporeNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS K01 AG086665NIA NIH HHS P30 AG066515NIA NIH HHS U24 AG072701NIBIB NIH HHSNIH HHS 1K01AG086665NIH HHS U01 AG024904NIH HHS U24AG072701Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizerPfizer Inc.PiramalPiramal ImagingPrevail TherapeuticsRocheSanofiServierSun Pharma Advanced Research CompanyTakedaTakeda Pharmaceutical CompanyTevaTransition TherapeuticsUCBUniversity of Southern CaliforniaVanqua BioVerilyVoyager TherapeuticsWeston Family FoundationYumanity Therapeutic
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative diseases (NDs). This study examined astrocytic contributions to neuropsychiatric symptoms (NPS), focusing on astrocytic protein activity and its relationship with NPS severity, accounting for clinical and pathological features of NDs.

methodsCerebrospinal astrocytic proteins (glial fibrillary acidic protein [GFAP], chitinase-3-like protein 1 [YKL-40], and aquaporin-4 [AQP4]) from Alzheimer's Disease Neuroimaging Initiative (ADNI) (AD) and Parkinson's Progression Markers Initiative (PPMI) (PD) were analyzed using K-means clustering. Six NPS domains, ND-specific pathologies (amyloid-beta/Aβ for AD, alpha-synuclein/αSyn for PD), and nonspecific pathology (phosphorylated tau/ptau) were assessed.

resultsIn both samples, three astrocytic clusters were identified, and the "highYKL|lowOthers" cluster (high YKL-40, low GFAP/AQP4) consistently showed lower ptau and NPS severity compared to the "highAll" cluster (high GFAP, YKL-40, AQP4). In PPMI, the "highYKL|lowOthers" cluster also attenuated the relationship between αSyn and NPS compared to the "highAll" cluster. DISCUSSION: Astrocytic activity relates to NPS, highlighting astrocytic proteins as potential therapeutic targets for NPS in NDs. HIGHLIGHTS: Astrocytic protein clusters were linked to NPS severity in AD and PD cohorts. The "highYKL|lowOthers" cluster showed lower ptau and NPS severity than "allhigh" cluster in AD and PD cohorts. Astrocytic proteins may serve as therapeutic targets for managing NPS in NDs.

Indexed as

Alzheimer DiseaseAstrocytesBrainParkinson DiseaseAgedAged, 80 and overalpha-SynucleinAmyloid beta-PeptidesAquaporin 4BiomarkersChitinase-3-Like Protein 1FemaleGlial Fibrillary Acidic ProteinHumansMaletau Proteinsalpha-SynucleinAmyloid beta-PeptidesAQP4 protein, humanAquaporin 4BiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1GFAP protein, humanGlial Fibrillary Acidic Proteintau ProteinsAlzheimer's diseaseastrocyteneuropsychiatric symptomsParkinson's diseasetauopathy

Identifiers

PMID40390204
PMCPMC12089078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.